Brief: Seelos Therapeutics Announces Positive Data From Study For Parkinson's Disease Pathology
07/07/2021 12:16
July 7 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES POSITIVE IN VIVO DATA
DEMONSTRATING DOWN-REGULATION OF SNCA MRNA AND PROTEIN
EXPRESSION FROM A GENE THERAPY STUDY OF SLS-004 UTILIZING
CRISPR-DCAS9 FOR PARKINSON'S DISEASE PATHOLOGY
* SEELOS THERAPEUTICS INC - PRELIMINARY FINDINGS SUPPORT
ADVANCING
SLS-004 PROGRAM INTO ADDITIONAL PRECLINICAL STUDIES OF
PARKINSON'S DISEASE UNDER SPONSORED RESEARCH AGREEMENT WITH DUKE
UNIVERSITY
* SEELOS THERAPEUTICS INC - A SINGLE DOSE OF SLS-004
PRODUCED A
THERAPEUTICALLY DESIRABLE 27% REDUCTION IN SNCA MRNA AND 40%
REDUCTION IN SNCA PROTEIN EXPRESSION IN PRELIMINARY FINDINGS
Source text for Eikon: ID:nPn6wqNvpa
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio